Banque Cantonale Vaudoise Sells 2,543 Shares of Intuitive Surgical, Inc. $ISRG

Banque Cantonale Vaudoise lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 14.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,816 shares of the medical equipment provider’s stock after selling 2,543 shares during the period. Banque Cantonale Vaudoise’s holdings in Intuitive Surgical were worth $6,627,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in ISRG. Norges Bank bought a new position in Intuitive Surgical in the second quarter valued at $2,569,260,000. Rakuten Investment Management Inc. purchased a new stake in Intuitive Surgical during the third quarter valued at about $388,436,000. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 2.1% during the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after purchasing an additional 670,302 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Intuitive Surgical by 41.3% during the third quarter. Victory Capital Management Inc. now owns 1,941,310 shares of the medical equipment provider’s stock worth $868,212,000 after purchasing an additional 567,483 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its holdings in shares of Intuitive Surgical by 27.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,089,293 shares of the medical equipment provider’s stock worth $591,933,000 after purchasing an additional 231,980 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 0.7%

NASDAQ ISRG opened at $493.53 on Tuesday. The firm has a market capitalization of $175.27 billion, a PE ratio of 62.55, a P/E/G ratio of 3.78 and a beta of 1.66. The stock’s 50 day moving average is $520.00 and its 200 day moving average is $512.68. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. The business had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.21 earnings per share. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In related news, SVP Patricia L. Wadors sold 220 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total value of $109,936.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mark Brosius sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $547.36, for a total transaction of $2,463,120.00. Following the transaction, the senior vice president directly owned 907 shares of the company’s stock, valued at approximately $496,455.52. This trade represents a 83.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 37,261 shares of company stock valued at $19,690,721 in the last quarter. 0.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ISRG shares. Citigroup reiterated a “neutral” rating and set a $590.00 price objective (down from $635.00) on shares of Intuitive Surgical in a research report on Friday, January 23rd. Piper Sandler restated an “overweight” rating and issued a $620.00 target price (up from $610.00) on shares of Intuitive Surgical in a research report on Friday, January 23rd. Royal Bank Of Canada upped their target price on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. HSBC increased their price target on shares of Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $600.00 to $654.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $615.86.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.